CRSP - CRISPR Therapeutics AG
NASDAQ
->
Healthcare
->
Biotechnology
Zug,
Switzerland
Type: Equity
CRSP price evolution
CRSP
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 1 May 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $225.67 | $495.99 | $707.43 | $401.07 |
| Short term investments | $1517.15 | $1400.7 | $1304.21 | |
| Net receivables | $200 | |||
| Inventory | ||||
| Total current assets | $1943.89 | $2010.41 | $2119.62 | $1908.08 |
| Long term investments | $11.22 | $1.97 | ||
| Property, plant & equipment | $284.83 | $291.57 | $298.51 | $305.94 |
| Goodwill & intangible assets | $0 | $0.02 | ||
| Total noncurrent assets | $329.45 | $319.39 | $321.49 | |
| Total investments | $1528.36 | $1400.7 | $1306.19 | |
| Total assets | $2256.13 | $2339.85 | $2439.02 | $2229.57 |
| Current liabilities | ||||
| Accounts payable | $15.58 | $9.45 | $16.46 | $38.15 |
| Deferred revenue | $17.34 | $17.61 | $18.12 | |
| Short long term debt | $16.45 | $15.99 | $15.63 | |
| Total current liabilities | $89.81 | $127.82 | $118.99 | $108.79 |
| Long term debt | $214.85 | $218.94 | $223.01 | |
| Total noncurrent liabilities | $231.08 | $236.09 | $237.98 | |
| Total debt | $231.3 | $234.93 | $238.63 | |
| Total liabilities | $316.47 | $358.9 | $355.08 | $346.77 |
| Shareholders' equity | ||||
| Retained earnings | -$1328.64 | -$1242.7 | -$1116.29 | -$999.7 |
| Other shareholder equity | $10.56 | -$2.88 | -$1.55 | $1.91 |
| Total shareholder equity | $1980.95 | $2083.94 | $1882.8 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $401.07 | $223.52 | $939.94 | $1185.47 |
| Short term investments | $1304.21 | $1603.43 | $1456.1 | $521.71 |
| Net receivables | $200 | $0.3 | $0.14 | |
| Inventory | ||||
| Total current assets | $1908.08 | $1853.03 | $2417.51 | $1716.62 |
| Long term investments | $1.97 | $53.13 | ||
| Property, plant & equipment | $305.94 | $320.56 | $312.04 | $93.03 |
| Goodwill & intangible assets | $0.02 | $0.07 | $0.13 | $0.18 |
| Total noncurrent assets | $321.49 | $390.03 | $334.36 | $111.35 |
| Total investments | $1306.19 | $1656.56 | $1456.1 | $521.71 |
| Total assets | $2229.57 | $2243.06 | $2751.88 | $1827.97 |
| Current liabilities | ||||
| Accounts payable | $38.15 | $27.43 | $14.82 | $9.09 |
| Deferred revenue | $18.12 | $12.32 | $13.33 | $14.12 |
| Short long term debt | $15.63 | $15.84 | $12.16 | $11.36 |
| Total current liabilities | $108.79 | $121.11 | $119.88 | $94.26 |
| Long term debt | $223.01 | $228.18 | $212.87 | $50.07 |
| Total noncurrent liabilities | $237.98 | $246.47 | $232.53 | $69.47 |
| Total debt | $238.63 | $244.02 | $225.03 | $61.43 |
| Total liabilities | $346.77 | $367.58 | $352.42 | $163.73 |
| Shareholders' equity | ||||
| Retained earnings | -$999.7 | -$846.09 | -$195.91 | -$573.58 |
| Other shareholder equity | $1.91 | -$15.65 | -$5.07 | -$0.08 |
| Total shareholder equity | $1882.8 | $1875.48 | $2399.46 | $1664.23 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.6 | $0.52 | $0.5 | $201.21 |
| Cost of revenue | ||||
| Gross Profit | $0.52 | $0.5 | $201.21 | |
| Operating activities | ||||
| Research & development | $132.3 | $123.14 | $115.14 | |
| Selling, general & administrative | $19.48 | $17.95 | $16.48 | |
| Total operating expenses | $110.73 | $151.78 | $141.09 | $131.62 |
| Operating income | -$151.26 | -$140.59 | $69.58 | |
| Income from continuing operations | ||||
| EBIT | -$125.12 | -$115.87 | $89.58 | |
| Income tax expense | $0.88 | $1.29 | $0.72 | $0.23 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$85.94 | -$126.41 | -$116.59 | $89.35 |
| Income (for common shares) | -$126.41 | -$116.59 | $89.35 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $371.21 | $1.2 | $914.96 | $0.72 |
| Cost of revenue | ||||
| Gross Profit | $371.21 | $1.2 | $914.96 | $0.72 |
| Operating activities | ||||
| Research & development | $517.58 | $571.89 | $438.63 | $266.95 |
| Selling, general & administrative | $76.16 | $102.46 | $102.8 | $88.21 |
| Total operating expenses | $593.74 | $674.36 | $541.43 | $355.15 |
| Operating income | -$222.54 | -$673.16 | $373.53 | -$354.44 |
| Income from continuing operations | ||||
| EBIT | -$150.72 | -$650.5 | $379.53 | -$348.06 |
| Income tax expense | $2.89 | -$0.33 | $1.87 | $0.81 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$153.61 | -$650.17 | $377.66 | -$348.87 |
| Income (for common shares) | -$153.61 | -$650.17 | $377.66 | -$348.87 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$126.41 | -$116.59 | $89.35 | |
| Operating activities | ||||
| Depreciation | $4.84 | $4.83 | $4.9 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $23.67 | $19.41 | $18.42 | |
| Total cash flows from operations | -$95.58 | $109.75 | -$96.07 | |
| Investing activities | ||||
| Capital expenditures | -$0.71 | -$0.72 | -$0.74 | |
| Investments | -$126.2 | -$97.08 | -$80.72 | |
| Total cash flows from investing | -$386.31 | -$126.91 | -$97.8 | -$81.45 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0.47 | $305.93 | $38.94 | |
| Net borrowings | ||||
| Total cash flows from financing | $315.11 | -$0.47 | $305.93 | $38.94 |
| Effect of exchange rate | $0.07 | $0 | -$0.01 | $0.06 |
| Change in cash and equivalents | -$163.88 | -$222.95 | $317.88 | -$138.53 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$153.61 | -$650.17 | $377.66 | -$348.87 |
| Operating activities | ||||
| Depreciation | $19.84 | $24.17 | $17.95 | $9.18 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $81.03 | $97.95 | $102.39 | $66.02 |
| Total cash flows from operations | -$260.38 | -$495.74 | $538.97 | -$238.37 |
| Investing activities | ||||
| Capital expenditures | -$9.47 | -$37.19 | -$81.7 | -$18.36 |
| Investments | $386.62 | -$221.47 | -$953.73 | -$522.81 |
| Total cash flows from investing | $374.65 | -$258.65 | -$1035.43 | -$541.17 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $62.66 | $38.59 | $250.94 | $1016.15 |
| Net borrowings | ||||
| Total cash flows from financing | $62.66 | $38.59 | $250.94 | $1016.15 |
| Effect of exchange rate | $0.07 | -$0.08 | -$0.01 | $0.04 |
| Change in cash and equivalents | $177.01 | -$715.88 | -$245.52 | $236.66 |
News
Fundamentals
| Market cap | $3.39B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 85.34M |
| Revenue | $202.83M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$239.59M |
| Revenue Q/Q | InfinityT% |
| Revenue Y/Y | 19.31% |
| P/E ratio | -14.14 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 16.70 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 2.64 |
| EPS | -$2.81 |
|---|---|
| ROA | -10.34% |
| ROE | N/A |
| Debt/Equity | 0.18 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 21.64 |
| Quick ratio | N/A |